Cargando…
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
Anti-SARS-CoV-2 vaccines are safe and effective, also in individuals with allergic and immune-mediated diseases (IMDs). There are reports suggesting that vaccines may be able to trigger de-novo or exacerbate pre-existing IMDs in predisposed individuals. Eosinophilic granulomatosis with polyangiitis...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144767/ https://www.ncbi.nlm.nih.gov/pubmed/35632472 http://dx.doi.org/10.3390/vaccines10050716 |
_version_ | 1784716128529940480 |
---|---|
author | Nappi, Emanuele De Santis, Maria Paoletti, Giovanni Pelaia, Corrado Terenghi, Fabrizia Pini, Daniela Ciccarelli, Michele Selmi, Carlo Francesco Puggioni, Francesca Canonica, Giorgio Walter Heffler, Enrico |
author_facet | Nappi, Emanuele De Santis, Maria Paoletti, Giovanni Pelaia, Corrado Terenghi, Fabrizia Pini, Daniela Ciccarelli, Michele Selmi, Carlo Francesco Puggioni, Francesca Canonica, Giorgio Walter Heffler, Enrico |
author_sort | Nappi, Emanuele |
collection | PubMed |
description | Anti-SARS-CoV-2 vaccines are safe and effective, also in individuals with allergic and immune-mediated diseases (IMDs). There are reports suggesting that vaccines may be able to trigger de-novo or exacerbate pre-existing IMDs in predisposed individuals. Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, eosinophilia, and eosinophil-rich granulomatous inflammation in various tissues. We describe the case of a 63-year-old man who experienced cardiac, pulmonary, and neurological involvement one day after the administration of the booster dose of anti-SARS-CoV-2 vaccine (mRNA-1273). A diagnosis of EGPA was made and the patient was treated with high-dose steroids and cyclophosphamide, with a good clinical response. Interestingly, our patient had experienced a significant worsening of his pre-existing asthma six months earlier, just after the first two vaccine shots with the ChAdOx1 anti-SARS-CoV-2 vaccine. It is impossible to know whether our patient would have had developed EGPA following natural SARS-CoV-2 infection or at some point in his life regardless of infectious stimuli. Nevertheless, our report may suggest that caution should be paid during the administration of additional vaccine doses in individuals who experienced an increase in IMD severity that persisted over time following previous vaccine shots. |
format | Online Article Text |
id | pubmed-9144767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91447672022-05-29 New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine Nappi, Emanuele De Santis, Maria Paoletti, Giovanni Pelaia, Corrado Terenghi, Fabrizia Pini, Daniela Ciccarelli, Michele Selmi, Carlo Francesco Puggioni, Francesca Canonica, Giorgio Walter Heffler, Enrico Vaccines (Basel) Case Report Anti-SARS-CoV-2 vaccines are safe and effective, also in individuals with allergic and immune-mediated diseases (IMDs). There are reports suggesting that vaccines may be able to trigger de-novo or exacerbate pre-existing IMDs in predisposed individuals. Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, eosinophilia, and eosinophil-rich granulomatous inflammation in various tissues. We describe the case of a 63-year-old man who experienced cardiac, pulmonary, and neurological involvement one day after the administration of the booster dose of anti-SARS-CoV-2 vaccine (mRNA-1273). A diagnosis of EGPA was made and the patient was treated with high-dose steroids and cyclophosphamide, with a good clinical response. Interestingly, our patient had experienced a significant worsening of his pre-existing asthma six months earlier, just after the first two vaccine shots with the ChAdOx1 anti-SARS-CoV-2 vaccine. It is impossible to know whether our patient would have had developed EGPA following natural SARS-CoV-2 infection or at some point in his life regardless of infectious stimuli. Nevertheless, our report may suggest that caution should be paid during the administration of additional vaccine doses in individuals who experienced an increase in IMD severity that persisted over time following previous vaccine shots. MDPI 2022-05-03 /pmc/articles/PMC9144767/ /pubmed/35632472 http://dx.doi.org/10.3390/vaccines10050716 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Nappi, Emanuele De Santis, Maria Paoletti, Giovanni Pelaia, Corrado Terenghi, Fabrizia Pini, Daniela Ciccarelli, Michele Selmi, Carlo Francesco Puggioni, Francesca Canonica, Giorgio Walter Heffler, Enrico New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine |
title | New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine |
title_full | New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine |
title_fullStr | New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine |
title_full_unstemmed | New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine |
title_short | New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine |
title_sort | new onset of eosinophilic granulomatosis with polyangiitis following mrna-based covid-19 vaccine |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144767/ https://www.ncbi.nlm.nih.gov/pubmed/35632472 http://dx.doi.org/10.3390/vaccines10050716 |
work_keys_str_mv | AT nappiemanuele newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT desantismaria newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT paolettigiovanni newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT pelaiacorrado newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT terenghifabrizia newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT pinidaniela newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT ciccarellimichele newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT selmicarlofrancesco newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT puggionifrancesca newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT canonicagiorgiowalter newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine AT hefflerenrico newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine |